Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Disease Reports
treatment-resistant depressive disorder
MeSH D061218 - treatment-resistant depressive disorder
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D003866:
Depressive disorder
166 Companies
36 Drugs
$
Success rate
D061218:
Â
Treatment-resistant depressive disorder
1 Company
1 Drug
$
Success rate
Events Timeline
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Johnson & Johnson
Esketamine
Â
SpravatoÂ
2027-03-20Â
2019-03-05Â
$1,077 MÂ
Y2024Â
Clinical Trials
Historical Success Rate
Phase 1
64
%
9/14
Phase 2
35
%
9/26
Phase 3
56
%
14/25
Approved:
1
Overall Success rate:
12%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Johnson & Johnson
Esketamine
,
Escitalopram
,
Esmirtazapine
,
Doconexent
,
Terfenadine
,
Sodium chloride
,
Aspartame
,
Ago178
,
Gladem
,
Lexapro
,
Wellbutrin
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use